Share price at $23, was sort of priced in for SAMR approval and China sales.
But at $10/share, it's already priced the failure of SAMR approval, not even as for delay, imo.
Without Chinese label sales, BAL is expected to have around $300m annual revenue for FY18, that implies PE is around 25.
Bear in mind, Daigou is still playing a significant role. That's how a2 adn BAL have been so successful.
- Forums
- ASX - By Stock
- BAL
- FY18 Guide & Annual Results
FY18 Guide & Annual Results, page-44
-
- There are more pages in this discussion • 662 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online